News > Bharat Biotech Hopes Covaxin to be at least 60% Effective, Aims to Launch Vaccine in Q2 of 2021

Bharat Biotech Hopes Covaxin to be at least 60% Effective, Aims to Launch Vaccine in Q2 of 2021

India’s indigenous Coronavirus vaccine maker Bharat Biotech has said that they are expecting the immune shots to be at least 60 per cent effective.

Sai D Prasad, President, Quality Operations at Bharat Biotech, said, “The WHO, US FDA and even India’s Central Drugs Standard Control Organisation approve a respiratory vaccine if it achieves 50 per cent efficacy. For Covaxin, we aim to achieve at least 60 per cent but, it could also be more.”